Reuters reported that AstraZeneca and Bristol Myers Squibb are no longer in merger discussions, effectively ending deal speculation. The update follows earlier coverage claiming talks were underway and comes amid market sensitivity to potential antitrust scrutiny and R&D disruption. A deal of the kind previously rumored would have reshaped the global pharma landscape, but the latest statement from a senior source cited by Reuters indicates “no deal” and “no discussions.” AstraZeneca shares fell sharply after the earlier report and then partially rebounded after the Reuters clarification. For biotech and pharma, the development shifts attention back to execution and pipeline decisions inside each company rather than integration planning risk tied to any hypothetical merger timeline.